US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Innoviva

23.39

-0.2500-1.06%

Post-market: 23.390.00000.00%17:09 EST

Volume:683.54K

Turnover:16.01M

Market Cap:1.75B

PE:15.34

High:23.78

Open:23.57

Low:23.26

Close:23.64

52wk High:24.01

52wk Low:16.52

Shares:74.77M

Float Shares:69.40M

Volume Ratio:0.84

T/O Rate:0.98%

Dividend:- -

Dividend Rate:- -

EPS(TTM):1.52

EPS(LYR):0.3621

ROE:15.17%

ROA:8.16%

PB:1.73

PE(LYR):64.60

Loading ...

Overview Company News Filings

Innoviva to Join Oppenheimer Annual Healthcare Life Sciences Conference Fireside Chat

BTIG Initiates Innoviva at Buy With $35 Price Target

MT Newswires Live

Innoviva Initiated at Buy by BTIG

Innoviva Inc : Btig Initiates Coverage With Buy Rating; Target Price $35

THOMSON REUTERS

Innoviva initiated with a Buy at BTIG

Innoviva: Durable Royalty Backbone and High-Growth Hospital Portfolio Underpin Buy Rating and $35 Target

Armata Pharmaceuticals Extends Loan Maturities With Innoviva to 2027

Armata Advances Phage Therapy Candidate AP-SA02 to Phase 3 After Positive FDA Review

How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug

Simply Wall St.

Innoviva Is Maintained at Buy by HC Wainwright & Co.

Innoviva (INVA): Revisiting Valuation After a Strong Multi‑Year Share Price Run

Simply Wall St.

Innoviva Gets FDA Approval for Gonorrhea Drug

U.S. FDA Approves Nuzolvence® (Zoliflodacin), a First-in-Class, Single-Dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

THOMSON REUTERS

US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections

BRIEF-FDA Approved Nuzolvence (Zoliflodacin) To Treat Uncomplicated Urogenital Gonorrhea

FDA: Today Approved Nuzolvence (Zoliflodacin) Granules That Dissolve in Water to Treat Uncomplicated Urogenital Gonorrhea - Website

THOMSON REUTERS

Innoviva Specialty Therapeutics Publishes Positive Phase 3 Zoliflodacin Data in The Lancet

Innoviva Specialty Therapeutics Announces Publication in the Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

THOMSON REUTERS

Armata Pharmaceuticals Reports Positive Phase 2a Results for AP-SA02 in Staph Aureus Bacteremia

A Look at Innoviva's (INVA) Valuation Following Strong Earnings and New Share Buyback Program

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INVA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INVA\",,,,,undefined,":{"symbol":"INVA","market":"US","secType":"STK","nameCN":"Innoviva","latestPrice":23.39,"timestamp":1771621200000,"preClose":23.64,"halted":0,"volume":683537,"hourTrading":{"tag":"盘后","latestPrice":23.39,"preClose":23.39,"latestTime":"17:09 EST","volume":29159,"amount":682029.01,"timestamp":1771625375956,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010575296108291032,"floatShares":69396800,"shares":74769062,"eps":1.524879,"marketStatus":"Not Yet Opened","change":-0.25,"latestTime":"02-20 16:00:00 EST","open":23.57,"high":23.78,"low":23.26,"amount":16007651.839524,"amplitude":0.021997,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.524879,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":23.64,"preHourTrading":{"tag":"盘前","latestPrice":23.65,"preClose":23.64,"latestTime":"09:25 EST","volume":1231,"amount":28886.729708,"timestamp":1771597514801,"change":0.01,"changeRate":0.000423,"amplitude":0.024535},"postHourTrading":{"tag":"盘后","latestPrice":23.39,"preClose":23.39,"latestTime":"17:09 EST","volume":29159,"amount":682029.01,"timestamp":1771625375956,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8394810065062218,"impliedVol":0.373,"impliedVolPercentile":0.498},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INVA\",,,,,undefined,":{"symbol":"INVA","floatShares":69396800,"roa":"8.16%","roe":"15.17%","lyrEps":0.362058,"volumeRatio":0.8394810065062218,"shares":74769062,"dividePrice":0,"high":23.78,"amplitude":0.021997,"preClose":23.64,"low":23.26,"week52Low":16.52,"pbRate":"1.73","psRate":"4.50","week52High":24.01,"institutionHeld":0.7455,"latestPrice":23.39,"eps":1.524879,"divideRate":0,"volume":683537,"delay":0,"ttmEps":1.524879,"open":23.57,"prevYearClose":19.99,"prevWeekClose":22.7,"prevMonthClose":20,"prevQuarterClose":19.99,"fiveDayClose":22.44,"twentyDayClose":19.74,"sixtyDayClose":20.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INVA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-05","symbol":"INVA","fiscalQuarterEnding":"2025/09","expectedEps":0.46,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"post","actualEps":1.08},{"market":"US","date":"2025-08-06","symbol":"INVA","fiscalQuarterEnding":"2025/06","expectedEps":0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":0.77},{"market":"US","date":"2025-05-07","symbol":"INVA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":0.25},{"market":"US","date":"2025-02-26","symbol":"INVA","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740546000000,"reportTimeType":"post","actualEps":0.57},{"market":"US","date":"2024-11-06","symbol":"INVA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":0.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.4,"hold":0,"sell":0.2,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4,"analysts":5,"updateTime":1771390800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/INVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"INVA","date":"2026-02-20","current":15.338922,"percent":0.780247,"low":-22.913716,"twenty":3.676782,"median":5.373157,"eighty":17.367921,"high":50.287764,"avg":9.025518,"sd":12.444549,"marketCap":1767540625},"quantilePoints":[{"date":"2021-02-26","current":5.16446,"twenty":-19.3028,"median":4.606342,"eighty":9.734772,"marketCap":1158915097},{"date":"2021-03-05","current":5.200606,"twenty":-19.350738,"median":4.699714,"eighty":9.735579,"marketCap":1167026489},{"date":"2021-03-12","current":5.440078,"twenty":-19.350738,"median":4.7753,"eighty":9.735579,"marketCap":1220764459},{"date":"2021-03-19","current":5.539482,"twenty":-19.350738,"median":4.824209,"eighty":9.735579,"marketCap":1243070787},{"date":"2021-03-26","current":5.38134,"twenty":-19.3028,"median":4.895137,"eighty":9.734772,"marketCap":1207583448},{"date":"2021-04-01","current":5.403932,"twenty":-19.3028,"median":4.934954,"eighty":9.734772,"marketCap":1212653068},{"date":"2021-04-09","current":5.287269,"twenty":-19.350738,"median":4.974771,"eighty":9.735579,"marketCap":1186473740},{"date":"2021-04-16","current":5.37765,"twenty":-19.350738,"median":5.002877,"eighty":9.735579,"marketCap":1206755342},{"date":"2021-04-23","current":5.287269,"twenty":-19.350738,"median":5.035667,"eighty":9.735579,"marketCap":1186473740},{"date":"2021-04-30","current":4.587818,"twenty":-19.350738,"median":5.063773,"eighty":9.735579,"marketCap":1161121737},{"date":"2021-05-07","current":4.700009,"twenty":-19.350738,"median":5.063773,"eighty":9.735579,"marketCap":1189515980},{"date":"2021-05-14","current":5.156788,"twenty":-19.350738,"median":5.069575,"eighty":9.735579,"marketCap":1305121114},{"date":"2021-05-21","current":5.276993,"twenty":-19.350738,"median":5.089537,"eighty":9.735579,"marketCap":1335543518},{"date":"2021-05-28","current":5.389184,"twenty":-19.350738,"median":5.131002,"eighty":9.735579,"marketCap":1363937761},{"date":"2021-06-04","current":5.200863,"twenty":-19.350738,"median":5.156788,"eighty":9.735579,"marketCap":1316275995},{"date":"2021-06-11","current":5.048603,"twenty":-19.350738,"median":5.156788,"eighty":9.735579,"marketCap":1277740951},{"date":"2021-06-18","current":5.341102,"twenty":-19.350738,"median":5.162126,"eighty":9.735579,"marketCap":1351768799},{"date":"2021-06-25","current":5.409218,"twenty":-19.350738,"median":5.180882,"eighty":9.735579,"marketCap":1369008162},{"date":"2021-07-02","current":5.465314,"twenty":-19.350738,"median":5.188804,"eighty":9.735579,"marketCap":1383205283},{"date":"2021-07-09","current":5.393191,"twenty":-19.350738,"median":5.206589,"eighty":9.735579,"marketCap":1364951841},{"date":"2021-07-16","current":5.232918,"twenty":-19.350738,"median":5.232918,"eighty":9.735579,"marketCap":1324388636},{"date":"2021-07-23","current":5.353122,"twenty":-19.350738,"median":5.254827,"eighty":9.735579,"marketCap":1354811040},{"date":"2021-07-30","current":3.715923,"twenty":-19.350738,"median":5.264972,"eighty":9.735579,"marketCap":985433172},{"date":"2021-08-06","current":4.04087,"twenty":-6.072838,"median":5.264972,"eighty":9.735579,"marketCap":1071606454},{"date":"2021-08-13","current":4.295062,"twenty":2.761506,"median":5.264972,"eighty":9.735579,"marketCap":1139016198},{"date":"2021-08-20","current":4.177138,"twenty":2.806003,"median":5.264972,"eighty":9.735579,"marketCap":1107743637},{"date":"2021-08-27","current":3.84695,"twenty":2.834874,"median":5.264972,"eighty":9.735579,"marketCap":1020180463},{"date":"2021-09-03","current":4.025147,"twenty":2.881226,"median":5.264972,"eighty":9.735579,"marketCap":1067436779},{"date":"2021-09-10","current":4.069696,"twenty":2.891291,"median":5.264972,"eighty":9.735579,"marketCap":1079250858},{"date":"2021-09-17","current":4.101143,"twenty":2.905594,"median":5.264972,"eighty":9.735579,"marketCap":1087590208},{"date":"2021-09-24","current":4.240031,"twenty":2.941086,"median":5.264972,"eighty":9.735579,"marketCap":1124422336},{"date":"2021-10-01","current":4.460156,"twenty":2.973399,"median":5.264972,"eighty":9.735579,"marketCap":1182797785},{"date":"2021-10-08","current":4.420848,"twenty":3.003594,"median":5.264972,"eighty":9.735579,"marketCap":1172373598},{"date":"2021-10-15","current":4.352714,"twenty":3.022236,"median":5.264972,"eighty":9.735579,"marketCap":1154305007},{"date":"2021-10-22","current":4.255754,"twenty":3.039616,"median":5.264972,"eighty":9.735579,"marketCap":1128592011},{"date":"2021-10-29","current":3.919172,"twenty":3.063454,"median":5.264972,"eighty":9.735579,"marketCap":1212638907},{"date":"2021-11-05","current":4.06965,"twenty":3.078287,"median":5.264972,"eighty":9.735579,"marketCap":1259198682},{"date":"2021-11-12","current":3.988796,"twenty":3.144504,"median":5.264972,"eighty":9.735579,"marketCap":1234181489},{"date":"2021-11-19","current":3.829334,"twenty":3.278956,"median":5.264972,"eighty":9.735579,"marketCap":1184842027},{"date":"2021-11-26","current":3.800137,"twenty":3.310817,"median":5.264972,"eighty":9.735579,"marketCap":1175808040},{"date":"2021-12-03","current":3.674364,"twenty":3.366978,"median":5.264972,"eighty":9.735579,"marketCap":1136892408},{"date":"2021-12-10","current":3.690086,"twenty":3.399379,"median":5.264972,"eighty":9.735579,"marketCap":1141756862},{"date":"2021-12-17","current":3.910188,"twenty":3.434335,"median":5.264972,"eighty":9.735579,"marketCap":1209859219},{"date":"2021-12-23","current":3.950615,"twenty":3.463967,"median":5.264972,"eighty":9.735579,"marketCap":1222367815},{"date":"2021-12-31","current":3.874253,"twenty":3.495501,"median":5.264972,"eighty":9.735579,"marketCap":1198740467},{"date":"2022-01-07","current":3.930402,"twenty":3.516963,"median":5.260304,"eighty":9.734772,"marketCap":1216113517},{"date":"2022-01-14","current":3.766448,"twenty":3.526683,"median":5.260304,"eighty":9.734772,"marketCap":1165384210},{"date":"2022-01-21","current":3.631691,"twenty":3.530182,"median":5.260304,"eighty":9.734772,"marketCap":1123688890},{"date":"2022-01-28","current":3.600248,"twenty":3.537296,"median":5.260304,"eighty":9.734772,"marketCap":1113959982},{"date":"2022-02-04","current":3.512656,"twenty":3.548507,"median":5.260304,"eighty":9.734772,"marketCap":1086858023},{"date":"2022-02-11","current":5.031803,"twenty":3.560719,"median":5.260304,"eighty":9.734772,"marketCap":1337724869},{"date":"2022-02-18","current":5.225233,"twenty":3.568459,"median":5.269342,"eighty":9.734772,"marketCap":1389149097},{"date":"2022-02-25","current":5.065784,"twenty":3.574833,"median":5.269342,"eighty":9.734772,"marketCap":1346758855},{"date":"2022-03-04","current":4.513774,"twenty":3.582107,"median":5.269342,"eighty":9.734772,"marketCap":1200004892},{"date":"2022-03-11","current":4.937676,"twenty":3.590711,"median":5.269342,"eighty":9.734772,"marketCap":1312701003},{"date":"2022-03-18","current":4.971693,"twenty":3.59574,"median":5.269342,"eighty":9.734772,"marketCap":1321744519},{"date":"2022-03-25","current":5.126864,"twenty":3.60143,"median":5.269342,"eighty":9.734772,"marketCap":1362997424},{"date":"2022-04-01","current":5.166121,"twenty":3.609038,"median":5.269342,"eighty":9.734772,"marketCap":1373433852},{"date":"2022-04-08","current":5.20276,"twenty":3.621043,"median":5.269342,"eighty":9.734772,"marketCap":1383174518},{"date":"2022-04-14","current":4.980308,"twenty":3.626567,"median":5.269342,"eighty":9.734772,"marketCap":1324034762},{"date":"2022-04-22","current":4.666258,"twenty":3.63727,"median":5.269342,"eighty":9.734772,"marketCap":1240543342},{"date":"2022-04-29","current":6.33037,"twenty":3.649123,"median":5.279209,"eighty":9.734772,"marketCap":1186969681},{"date":"2022-05-06","current":5.731887,"twenty":3.654188,"median":5.29302,"eighty":9.734772,"marketCap":1074751826},{"date":"2022-05-13","current":5.895443,"twenty":3.660684,"median":5.306767,"eighty":9.734772,"marketCap":1105419193},{"date":"2022-05-20","current":6.055282,"twenty":3.684861,"median":5.317914,"eighty":9.734772,"marketCap":1135389574},{"date":"2022-05-27","current":5.746756,"twenty":3.690175,"median":5.332028,"eighty":9.734772,"marketCap":1077539768},{"date":"2022-06-03","current":5.698433,"twenty":3.692734,"median":5.341102,"eighty":9.734772,"marketCap":1068478955},{"date":"2022-06-10","current":5.512574,"twenty":3.702116,"median":5.365506,"eighty":9.734772,"marketCap":1033629674},{"date":"2022-06-17","current":5.493988,"twenty":3.715796,"median":5.371587,"eighty":9.734772,"marketCap":1030144746},{"date":"2022-06-24","current":5.486554,"twenty":3.727935,"median":5.373157,"eighty":9.735579,"marketCap":1028750775},{"date":"2022-07-01","current":5.534877,"twenty":3.748483,"median":5.389184,"eighty":9.735579,"marketCap":1037811588},{"date":"2022-07-08","current":5.382473,"twenty":3.755218,"median":5.393191,"eighty":9.735579,"marketCap":1009235177},{"date":"2022-07-15","current":5.352735,"twenty":3.760182,"median":5.393191,"eighty":9.735579,"marketCap":1003659292},{"date":"2022-07-22","current":5.41221,"twenty":3.770133,"median":5.409218,"eighty":9.735579,"marketCap":1014811062},{"date":"2022-07-29","current":10.046571,"twenty":3.785487,"median":5.413225,"eighty":9.758835,"marketCap":999583566},{"date":"2022-08-05","current":10.116631,"twenty":3.795068,"median":5.425245,"eighty":9.818411,"marketCap":1006554163},{"date":"2022-08-12","current":10.32681,"twenty":3.796195,"median":5.429252,"eighty":9.840354,"marketCap":1027465953},{"date":"2022-08-19","current":9.892439,"twenty":3.796195,"median":5.429252,"eighty":9.840354,"marketCap":984248254},{"date":"2022-08-26","current":9.338967,"twenty":3.796195,"median":5.429252,"eighty":9.775415,"marketCap":929180540},{"date":"2022-09-02","current":9.163818,"twenty":3.796195,"median":5.429252,"eighty":9.732367,"marketCap":911754048},{"date":"2022-09-09","current":9.268907,"twenty":3.796195,"median":5.429252,"eighty":9.707338,"marketCap":922209943},{"date":"2022-09-16","current":8.757471,"twenty":3.796195,"median":5.429252,"eighty":9.630338,"marketCap":871324587},{"date":"2022-09-23","current":8.267053,"twenty":3.796195,"median":5.429252,"eighty":9.579714,"marketCap":822530410},{"date":"2022-09-30","current":8.133939,"twenty":3.796195,"median":5.429252,"eighty":9.553725,"marketCap":809286276},{"date":"2022-10-07","current":8.687411,"twenty":3.796195,"median":5.429252,"eighty":9.509074,"marketCap":864353990},{"date":"2022-10-14","current":9.268907,"twenty":3.796195,"median":5.429252,"eighty":9.481881,"marketCap":922209943},{"date":"2022-10-21","current":9.458069,"twenty":3.796195,"median":5.429252,"eighty":9.462795,"marketCap":941030554},{"date":"2022-10-28","current":9.507111,"twenty":3.796195,"median":5.429252,"eighty":9.454174,"marketCap":945909972},{"date":"2022-11-04","current":9.093758,"twenty":3.796195,"median":5.429252,"eighty":9.416144,"marketCap":904783451},{"date":"2022-11-11","current":3.248503,"twenty":3.791136,"median":5.419645,"eighty":9.398806,"marketCap":950446979},{"date":"2022-11-18","current":3.231807,"twenty":3.779229,"median":5.41221,"eighty":9.375567,"marketCap":945562156},{"date":"2022-11-25","current":3.110167,"twenty":3.76699,"median":5.399413,"eighty":9.361853,"marketCap":909972732},{"date":"2022-12-02","current":3.16741,"twenty":3.7586,"median":5.389907,"eighty":9.33056,"marketCap":926720696},{"date":"2022-12-09","current":3.188875,"twenty":3.755171,"median":5.37765,"eighty":9.296797,"marketCap":933001183},{"date":"2022-12-16","current":3.04577,"twenty":3.73787,"median":5.373157,"eighty":9.268907,"marketCap":891131272},{"date":"2022-12-23","current":3.157869,"twenty":3.721737,"median":5.370871,"eighty":9.219774,"marketCap":923929369},{"date":"2022-12-30","current":3.160254,"twenty":3.712352,"median":5.36017,"eighty":9.204798,"marketCap":924627201},{"date":"2023-01-06","current":3.200801,"twenty":3.701355,"median":5.352735,"eighty":9.167406,"marketCap":936490342},{"date":"2023-01-13","current":3.188875,"twenty":3.692734,"median":5.333088,"eighty":9.128427,"marketCap":933001183},{"date":"2023-01-20","current":3.105397,"twenty":3.690153,"median":5.329081,"eighty":9.105671,"marketCap":908577068},{"date":"2023-01-27","current":3.026689,"twenty":3.683733,"median":5.3133,"eighty":9.078668,"marketCap":885548617},{"date":"2023-02-03","current":3.052925,"twenty":3.660478,"median":5.29997,"eighty":9.014694,"marketCap":893224768},{"date":"2023-02-10","current":2.92413,"twenty":3.653686,"median":5.287269,"eighty":8.978083,"marketCap":855541848},{"date":"2023-02-17","current":2.962291,"twenty":3.648628,"median":5.276993,"eighty":8.933954,"marketCap":866707157},{"date":"2023-02-24","current":2.866887,"twenty":3.638752,"median":5.254827,"eighty":8.904325,"marketCap":838793883},{"date":"2023-03-03","current":3.499917,"twenty":3.631691,"median":5.232918,"eighty":8.868252,"marketCap":748705718},{"date":"2023-03-10","current":3.436224,"twenty":3.621445,"median":5.215864,"eighty":8.835303,"marketCap":735080500},{"date":"2023-03-17","current":3.560425,"twenty":3.618049,"median":5.200863,"eighty":8.793592,"marketCap":761649675},{"date":"2023-03-24","current":3.614564,"twenty":3.609038,"median":5.188804,"eighty":8.750715,"marketCap":773231110},{"date":"2023-03-31","current":3.582717,"twenty":3.603966,"median":5.181688,"eighty":8.730663,"marketCap":766418501},{"date":"2023-04-06","current":3.700549,"twenty":3.603459,"median":5.166475,"eighty":8.69652,"marketCap":791625154},{"date":"2023-04-14","current":3.885258,"twenty":3.602952,"median":5.156788,"eighty":8.674168,"marketCap":831138285},{"date":"2023-04-21","current":3.770611,"twenty":3.602952,"median":5.144341,"eighty":8.639328,"marketCap":806612893},{"date":"2023-04-28","current":3.78335,"twenty":3.602952,"median":5.131002,"eighty":8.607948,"marketCap":809337937},{"date":"2023-05-05","current":3.564265,"twenty":3.59758,"median":5.112713,"eighty":8.591234,"marketCap":762471029},{"date":"2023-05-12","current":3.494309,"twenty":3.592693,"median":5.087608,"eighty":8.556531,"marketCap":814219493},{"date":"2023-05-19","current":3.710771,"twenty":3.591527,"median":5.071127,"eighty":8.536736,"marketCap":864657868},{"date":"2023-05-26","current":3.691093,"twenty":3.591527,"median":5.064054,"eighty":8.482623,"marketCap":860072561},{"date":"2023-06-02","current":3.68547,"twenty":3.591527,"median":5.048603,"eighty":8.459414,"marketCap":858762474},{"date":"2023-06-09","current":3.856953,"twenty":3.591527,"median":5.028738,"eighty":8.411843,"marketCap":898720148},{"date":"2023-06-16","current":3.702337,"twenty":3.591379,"median":5.018866,"eighty":8.377115,"marketCap":862692737},{"date":"2023-06-23","current":3.626435,"twenty":3.591083,"median":5.009226,"eighty":8.316656,"marketCap":845006553},{"date":"2023-06-30","current":3.584267,"twenty":3.588457,"median":4.997281,"eighty":8.273434,"marketCap":835180896},{"date":"2023-07-06","current":3.502743,"twenty":3.585402,"median":4.984566,"eighty":8.205703,"marketCap":816184624},{"date":"2023-07-14","current":3.502743,"twenty":3.582717,"median":4.97316,"eighty":8.092774,"marketCap":816184624},{"date":"2023-07-21","current":3.553344,"twenty":3.578604,"median":4.960924,"eighty":7.943882,"marketCap":827975413},{"date":"2023-07-24","current":3.646114,"twenty":3.578604,"median":4.951555,"eighty":7.851265,"marketCap":849591860},{"date":"2023-08-04","current":3.676782,"twenty":3.578604,"median":4.920901,"eighty":7.690116,"marketCap":857991903},{"date":"2023-08-11","current":3.796738,"twenty":3.578604,"median":4.878742,"eighty":7.636489,"marketCap":885984052},{"date":"2023-08-18","current":3.78558,"twenty":3.578604,"median":4.851698,"eighty":7.588225,"marketCap":883380131},{"date":"2023-08-25","current":3.70189,"twenty":3.578604,"median":4.810688,"eighty":7.51851,"marketCap":863850725},{"date":"2023-09-01","current":3.556827,"twenty":3.576513,"median":4.77312,"eighty":7.491696,"marketCap":829999755},{"date":"2023-09-08","current":3.492664,"twenty":3.575345,"median":4.737931,"eighty":7.464883,"marketCap":815027210},{"date":"2023-09-15","current":3.565196,"twenty":3.568459,"median":4.699861,"eighty":7.442002,"marketCap":831952695},{"date":"2023-09-22","current":3.607041,"twenty":3.565196,"median":4.672499,"eighty":7.427344,"marketCap":841717398},{"date":"2023-09-29","current":3.690731,"twenty":3.565196,"median":4.651074,"eighty":7.40053,"marketCap":861246804},{"date":"2023-10-05","current":3.654465,"twenty":3.565196,"median":4.62178,"eighty":7.325453,"marketCap":852784062},{"date":"2023-10-13","current":3.732576,"twenty":3.565158,"median":4.577072,"eighty":7.277188,"marketCap":871011507},{"date":"2023-10-19","current":3.640517,"twenty":3.565138,"median":4.547791,"eighty":7.210691,"marketCap":849529161},{"date":"2023-10-27","current":3.503823,"twenty":3.564003,"median":4.517808,"eighty":7.142836,"marketCap":817631131},{"date":"2023-11-03","current":17.063397,"twenty":3.561951,"median":4.504077,"eighty":7.079305,"marketCap":851071044},{"date":"2023-11-10","current":17.320376,"twenty":3.561951,"median":4.504077,"eighty":7.079305,"marketCap":863888379},{"date":"2023-11-17","current":17.538808,"twenty":3.561951,"median":4.504077,"eighty":7.079305,"marketCap":874783113},{"date":"2023-11-24","current":17.847182,"twenty":3.561951,"median":4.504077,"eighty":7.079305,"marketCap":890163915},{"date":"2023-12-01","current":17.795787,"twenty":3.561951,"median":4.504077,"eighty":7.079305,"marketCap":887600448},{"date":"2023-12-08","current":18.96504,"twenty":3.562009,"median":4.505701,"eighty":7.088421,"marketCap":945919323},{"date":"2023-12-15","current":19.761675,"twenty":3.562009,"median":4.505701,"eighty":7.088421,"marketCap":985653061},{"date":"2023-12-22","current":20.828137,"twenty":3.562009,"median":4.505701,"eighty":7.088421,"marketCap":1038845001},{"date":"2023-12-27","current":20.905231,"twenty":3.562009,"median":4.505701,"eighty":7.088421,"marketCap":1042690202},{"date":"2024-01-05","current":21.560527,"twenty":3.561836,"median":4.503999,"eighty":7.027752,"marketCap":1075374406},{"date":"2024-01-12","current":21.085116,"twenty":3.561836,"median":4.503999,"eighty":7.027752,"marketCap":1051662336},{"date":"2024-01-19","current":20.622554,"twenty":3.561778,"median":4.49256,"eighty":7.016745,"marketCap":1028591133},{"date":"2024-01-26","current":21.226454,"twenty":3.561836,"median":4.503999,"eighty":7.027752,"marketCap":1058711871},{"date":"2024-02-02","current":20.930929,"twenty":3.561836,"median":4.503999,"eighty":7.027752,"marketCap":1043971935},{"date":"2024-02-09","current":20.044352,"twenty":3.561836,"median":4.513774,"eighty":7.101292,"marketCap":999752130},{"date":"2024-02-16","current":20.558309,"twenty":3.561836,"median":4.547791,"eighty":7.207473,"marketCap":1025386800},{"date":"2024-02-23","current":19.890164,"twenty":3.561836,"median":4.587818,"eighty":7.231069,"marketCap":992061729},{"date":"2024-03-01","current":5.448662,"twenty":3.561894,"median":4.62178,"eighty":7.292204,"marketCap":979244394},{"date":"2024-03-08","current":5.305239,"twenty":3.561894,"median":4.661024,"eighty":7.292204,"marketCap":953468181},{"date":"2024-03-15","current":5.178589,"twenty":3.561894,"median":4.674502,"eighty":7.292204,"marketCap":930706341},{"date":"2024-03-22","current":5.273577,"twenty":3.561894,"median":4.702535,"eighty":7.292204,"marketCap":947777721},{"date":"2024-03-28","current":5.379118,"twenty":3.563872,"median":4.737931,"eighty":7.292204,"marketCap":966745921},{"date":"2024-04-05","current":5.15748,"twenty":3.564451,"median":4.784027,"eighty":7.295421,"marketCap":926912701},{"date":"2024-04-12","current":5.175071,"twenty":3.564451,"median":4.820187,"eighty":7.295421,"marketCap":930074068},{"date":"2024-04-19","current":5.168035,"twenty":3.568459,"median":4.852978,"eighty":7.295421,"marketCap":928809521},{"date":"2024-04-26","current":5.273577,"twenty":3.576068,"median":4.884521,"eighty":7.292204,"marketCap":947777721},{"date":"2024-05-03","current":5.346639,"twenty":3.577349,"median":4.923818,"eighty":7.292204,"marketCap":960908730},{"date":"2024-05-10","current":5.26993,"twenty":3.577349,"median":4.944323,"eighty":7.292204,"marketCap":955907253},{"date":"2024-05-17","current":5.501257,"twenty":3.577349,"median":4.972084,"eighty":7.292204,"marketCap":997867552},{"date":"2024-05-24","current":5.435848,"twenty":3.577349,"median":4.980068,"eighty":7.292204,"marketCap":986003044},{"date":"2024-05-31","current":5.284374,"twenty":3.578976,"median":4.999541,"eighty":7.292204,"marketCap":958527342},{"date":"2024-06-07","current":5.635518,"twenty":3.582717,"median":5.011302,"eighty":7.292204,"marketCap":1022221015},{"date":"2024-06-14","current":5.5047,"twenty":3.586773,"median":5.024798,"eighty":7.295421,"marketCap":998492000},{"date":"2024-06-21","current":5.532241,"twenty":3.589018,"median":5.033735,"eighty":7.298639,"marketCap":1003487582},{"date":"2024-06-28","current":5.576994,"twenty":3.589408,"median":5.048603,"eighty":7.301857,"marketCap":1011605403},{"date":"2024-07-05","current":5.621748,"twenty":3.589408,"median":5.064054,"eighty":7.301857,"marketCap":1019723224},{"date":"2024-07-12","current":5.773222,"twenty":3.591379,"median":5.069575,"eighty":7.301857,"marketCap":1047198927},{"date":"2024-07-15","current":5.759451,"twenty":3.594273,"median":5.071127,"eighty":7.301857,"marketCap":1044701135},{"date":"2024-08-02","current":8.298703,"twenty":3.617753,"median":5.091658,"eighty":7.336178,"marketCap":1206830528},{"date":"2024-08-09","current":7.851287,"twenty":3.625972,"median":5.114717,"eighty":7.405997,"marketCap":1141765533},{"date":"2024-08-16","current":7.92012,"twenty":3.63145,"median":5.130178,"eighty":7.433779,"marketCap":1151775532},{"date":"2024-08-23","current":8.019068,"twenty":3.642748,"median":5.141948,"eighty":7.45523,"marketCap":1166164906},{"date":"2024-08-30","current":8.216963,"twenty":3.653491,"median":5.148915,"eighty":7.487406,"marketCap":1194943654},{"date":"2024-09-06","current":8.350328,"twenty":3.670087,"median":5.157134,"eighty":7.502422,"marketCap":1214338027},{"date":"2024-09-13","current":8.436369,"twenty":3.676298,"median":5.163293,"eighty":7.577349,"marketCap":1226850526},{"date":"2024-09-20","current":8.462181,"twenty":3.690086,"median":5.171553,"eighty":7.606458,"marketCap":1230604276},{"date":"2024-09-27","current":8.14813,"twenty":3.692332,"median":5.181495,"eighty":7.668665,"marketCap":1184933655},{"date":"2024-10-04","current":8.389046,"twenty":3.69637,"median":5.18682,"eighty":7.75512,"marketCap":1219968652},{"date":"2024-10-11","current":8.384744,"twenty":3.702248,"median":5.197757,"eighty":7.813325,"marketCap":1219343027},{"date":"2024-10-18","current":8.677285,"twenty":3.710669,"median":5.204902,"eighty":7.881401,"marketCap":1261885524},{"date":"2024-10-25","current":8.518108,"twenty":3.715796,"median":5.212966,"eighty":7.941415,"marketCap":1238737401},{"date":"2024-10-31","current":8.47939,"twenty":3.724703,"median":5.225371,"eighty":7.980349,"marketCap":1233106776},{"date":"2024-11-08","current":19.38384,"twenty":3.738799,"median":5.234878,"eighty":8.063603,"marketCap":1252021620},{"date":"2024-11-15","current":18.647254,"twenty":3.755218,"median":5.252468,"eighty":8.134453,"marketCap":1204444798},{"date":"2024-11-22","current":18.4728,"twenty":3.757873,"median":5.264972,"eighty":8.162272,"marketCap":1193176603},{"date":"2024-11-29","current":18.404956,"twenty":3.761135,"median":5.273577,"eighty":8.218684,"marketCap":1188794528},{"date":"2024-12-06","current":18.337113,"twenty":3.76629,"median":5.280999,"eighty":8.27455,"marketCap":1184412452},{"date":"2024-12-13","current":17.978512,"twenty":3.772706,"median":5.287503,"eighty":8.30802,"marketCap":1161250052},{"date":"2024-12-20","current":17.377613,"twenty":3.775845,"median":5.297939,"eighty":8.332259,"marketCap":1122437382},{"date":"2024-12-27","current":17.106239,"twenty":3.775845,"median":5.308757,"eighty":8.365871,"marketCap":1104909079},{"date":"2025-01-03","current":16.863941,"twenty":3.778884,"median":5.313054,"eighty":8.386465,"marketCap":1089258809},{"date":"2025-01-10","current":16.776714,"twenty":3.785487,"median":5.325718,"eighty":8.394256,"marketCap":1083624712},{"date":"2025-01-17","current":17.881593,"twenty":3.78558,"median":5.332774,"eighty":8.438975,"marketCap":1154989944},{"date":"2025-01-24","current":17.997896,"twenty":3.78558,"median":5.338757,"eighty":8.461325,"marketCap":1162502074},{"date":"2025-01-31","current":18.317729,"twenty":3.788922,"median":5.349748,"eighty":8.487134,"marketCap":1183160430},{"date":"2025-02-07","current":17.697446,"twenty":3.794072,"median":5.352928,"eighty":8.518108,"marketCap":1143095739},{"date":"2025-02-14","current":17.658678,"twenty":3.794072,"median":5.352928,"eighty":8.518108,"marketCap":1140591695},{"date":"2025-02-21","current":17.5133,"twenty":3.794072,"median":5.352928,"eighty":8.518108,"marketCap":1131201533},{"date":"2025-02-28","current":47.022735,"twenty":3.794072,"median":5.352928,"eighty":8.518108,"marketCap":1099955814},{"date":"2025-03-07","current":47.129909,"twenty":3.793184,"median":5.352735,"eighty":8.515527,"marketCap":1102462836},{"date":"2025-03-14","current":46.594038,"twenty":3.793184,"median":5.352735,"eighty":8.536093,"marketCap":1089927727},{"date":"2025-03-21","current":46.111753,"twenty":3.793184,"median":5.353122,"eighty":8.555967,"marketCap":1078646129},{"date":"2025-03-28","current":47.906923,"twenty":3.793184,"median":5.353122,"eighty":8.573144,"marketCap":1120638744},{"date":"2025-04-04","current":48.442795,"twenty":3.793184,"median":5.353122,"eighty":8.676508,"marketCap":1133173853},{"date":"2025-04-11","current":45.817024,"twenty":3.794072,"median":5.353676,"eighty":8.711262,"marketCap":1071751819},{"date":"2025-04-17","current":48.469588,"twenty":3.794072,"median":5.353676,"eighty":8.786896,"marketCap":1133800609},{"date":"2025-04-25","current":49.321723,"twenty":3.793184,"median":5.353122,"eighty":9.089554,"marketCap":1153733755},{"date":"2025-05-02","current":50.046254,"twenty":3.793184,"median":5.353122,"eighty":9.161016,"marketCap":1170681966},{"date":"2025-05-09","current":-19.529213,"twenty":3.785799,"median":5.350974,"eighty":9.242284,"marketCap":1166362714},{"date":"2025-05-16","current":-19.266441,"twenty":3.780033,"median":5.341102,"eighty":9.242284,"marketCap":1150668921},{"date":"2025-05-23","current":-19.781474,"twenty":3.767718,"median":5.333088,"eighty":9.242284,"marketCap":1181428755},{"date":"2025-05-30","current":-20.485703,"twenty":3.762308,"median":5.329081,"eighty":9.242284,"marketCap":1223488121},{"date":"2025-06-06","current":-22.251531,"twenty":3.756175,"median":5.3133,"eighty":9.242284,"marketCap":1328950412},{"date":"2025-06-13","current":-22.493281,"twenty":3.746652,"median":5.308757,"eighty":9.242284,"marketCap":1343388702},{"date":"2025-06-20","current":-22.556346,"twenty":3.728267,"median":5.297483,"eighty":9.247889,"marketCap":1347155212},{"date":"2025-06-27","current":-21.431682,"twenty":3.715923,"median":5.287386,"eighty":9.247889,"marketCap":1279985777},{"date":"2025-07-03","current":-20.191398,"twenty":3.710771,"median":5.282687,"eighty":9.247889,"marketCap":1205911073},{"date":"2025-07-11","current":-20.033735,"twenty":3.702337,"median":5.273644,"eighty":9.247889,"marketCap":1196494797},{"date":"2025-07-18","current":-20.895627,"twenty":3.69631,"median":5.262238,"eighty":9.247889,"marketCap":1247970439},{"date":"2025-07-25","current":-19.886583,"twenty":3.691093,"median":5.251388,"eighty":9.247889,"marketCap":1187706273},{"date":"2025-08-01","current":-19.098267,"twenty":3.68547,"median":5.233898,"eighty":9.247889,"marketCap":1140624893},{"date":"2025-08-08","current":30.100854,"twenty":3.676782,"median":5.228182,"eighty":9.268907,"marketCap":1163367918},{"date":"2025-08-15","current":34.046903,"twenty":3.676782,"median":5.228182,"eighty":9.402021,"marketCap":1315878772},{"date":"2025-08-22","current":32.563059,"twenty":3.676782,"median":5.228182,"eighty":9.472081,"marketCap":1258529649},{"date":"2025-08-29","current":32.660894,"twenty":3.676782,"median":5.233898,"eighty":9.500105,"marketCap":1262310910},{"date":"2025-09-05","current":34.112127,"twenty":3.676298,"median":5.250308,"eighty":9.578571,"marketCap":1318399612},{"date":"2025-09-12","current":31.682535,"twenty":3.676782,"median":5.255916,"eighty":9.871421,"marketCap":1224498302},{"date":"2025-09-19","current":32.432611,"twenty":3.676782,"median":5.271818,"eighty":10.018547,"marketCap":1253487968},{"date":"2025-09-26","current":30.28022,"twenty":3.676782,"median":5.279175,"eighty":10.137649,"marketCap":1170300229},{"date":"2025-10-03","current":28.788222,"twenty":3.676782,"median":5.287269,"eighty":10.32681,"marketCap":1112636002},{"date":"2025-10-10","current":28.453949,"twenty":3.676782,"median":5.295111,"eighty":16.776714,"marketCap":1099716694},{"date":"2025-10-17","current":28.12783,"twenty":3.676782,"median":5.306998,"eighty":16.980244,"marketCap":1087112491},{"date":"2025-10-24","current":29.774735,"twenty":3.676782,"median":5.315568,"eighty":17.135315,"marketCap":1150763715},{"date":"2025-10-31","current":29.269249,"twenty":3.676782,"median":5.33034,"eighty":17.307527,"marketCap":1131227201},{"date":"2025-11-07","current":12.083391,"twenty":3.676782,"median":5.336998,"eighty":17.367921,"marketCap":1538747295},{"date":"2025-11-14","current":13.034561,"twenty":3.676782,"median":5.348175,"eighty":17.367921,"marketCap":1659873176},{"date":"2025-11-21","current":12.423933,"twenty":3.676782,"median":5.353676,"eighty":17.367921,"marketCap":1582113351},{"date":"2025-11-28","current":12.758604,"twenty":3.676782,"median":5.361528,"eighty":17.367921,"marketCap":1624731717},{"date":"2025-12-05","current":12.212562,"twenty":3.676782,"median":5.368564,"eighty":17.367921,"marketCap":1555196489},{"date":"2025-12-12","current":12.106876,"twenty":3.676782,"median":5.372717,"eighty":17.367921,"marketCap":1541738058},{"date":"2025-12-19","current":11.783948,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1500615074},{"date":"2025-12-26","current":11.607805,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1478184355},{"date":"2026-01-02","current":11.736977,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1494633549},{"date":"2026-01-09","current":11.537348,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1469212068},{"date":"2026-01-16","current":11.601934,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1477436665},{"date":"2026-01-23","current":11.590191,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1475941283},{"date":"2026-01-30","current":11.596062,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1476688974},{"date":"2026-02-06","current":12.664662,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1612768667},{"date":"2026-02-13","current":13.175475,"twenty":3.676782,"median":5.373131,"eighty":17.367921,"marketCap":1677817751},{"date":"2026-02-20","current":13.880046,"twenty":3.676782,"median":5.373157,"eighty":17.367921,"marketCap":1767540625}],"updateTime":1771819636692},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INVA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612056407","title":"Innoviva to Join Oppenheimer Annual Healthcare Life Sciences Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2612056407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612056407?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:01","pubTimestamp":1771506068,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innoviva Inc. published the original content used to generate this news brief via Business Wire  on February 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL18pNnK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2612548194","title":"BTIG Initiates Innoviva at Buy With $35 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612548194","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612548194?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:22","pubTimestamp":1771330923,"startTime":"0","endTime":"0","summary":"Innoviva (INVA) has an average rating of overweight and mean price target of $33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INVA"],"gpt_icon":0},{"id":"2612599284","title":"Innoviva Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2612599284","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612599284?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:43","pubTimestamp":1771328580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 06:43 ET (11:43 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2612595724","title":"Innoviva Inc : Btig Initiates Coverage With Buy Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2612595724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612595724?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:39","pubTimestamp":1771328390,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0N1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2612456476","title":"Innoviva initiated with a Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2612456476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612456476?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:16","pubTimestamp":1771326989,"startTime":"0","endTime":"0","summary":"BTIG initiated coverage of Innoviva (INVA) with a Buy rating and $35 price target Innoviva is positioned to capture more than $1.2B in royalties th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/innoviva-initiated-with-a-buy-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/innoviva-initiated-with-a-buy-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2612797456","title":"Innoviva: Durable Royalty Backbone and High-Growth Hospital Portfolio Underpin Buy Rating and $35 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612797456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612797456?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:16","pubTimestamp":1771326968,"startTime":"0","endTime":"0","summary":"Julian Harrison, an analyst from BTIG, has initiated a new Buy rating on Innoviva (INVA). Julian Harrison has given his Buy rating due to a combina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/innoviva-durable-royalty-backbone-and-high-growth-hospital-portfolio-underpin-buy-rating-and-35-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/innoviva-durable-royalty-backbone-and-high-growth-hospital-portfolio-underpin-buy-rating-and-35-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4595","INVA","BK4023","BK4600","BK4007"],"gpt_icon":0},{"id":"2606248674","title":"Armata Pharmaceuticals Extends Loan Maturities With Innoviva to 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2606248674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606248674?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:01","pubTimestamp":1769432513,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals Inc. has announced amendments to four existing credit agreements with Innoviva Strategic Opportunities LLC, a subsidiary of Innoviva, Inc., a principal shareholder of Armata. The amendments, entered into on January 23, 2026, extend the maturity date of each loan to June 1, 2027. These agreements involve Armata as the borrower, Innoviva Sub as the lender, and certain Armata subsidiaries as guarantors. The amendments apply to credit and security agreements originally dated March 12, 2025, March 4, 2024, July 10, 2023, and January 10, 2023.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gatherin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL66wZVz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARMP","BK4139","INVA","BK4007"],"gpt_icon":0},{"id":"2603686679","title":"Armata Advances Phage Therapy Candidate AP-SA02 to Phase 3 After Positive FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686679","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686679?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:01","pubTimestamp":1768305709,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals Inc. has announced that its Phase 2a diSArm study demonstrated the first evidence of efficacy for phage therapy in a randomized controlled trial, targeting complicated Staphylococcus aureus bacteremia. Following feedback from the U.S. Food and Drug Administration  after an End-of-Phase 2 meeting, the FDA agreed that the safety and efficacy data support advancing Armata's bacteriophage product candidate, AP-SA02, to a Phase 3 clinical trial. Armata intends to initiate this pivotal superiority study later this year, which would be the first superiority-based pivotal trial for an antibacterial drug candidate in several decades. The company is currently addressing FDA recommendations on study design and manufacturing in preparation for the upcoming trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL477yNb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARMP","BK4007","BK4139","INVA"],"gpt_icon":0},{"id":"2593210430","title":"How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2593210430","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593210430?lang=en_us&edition=fundamental","pubTime":"2025-12-23 02:11","pubTimestamp":1766427114,"startTime":"0","endTime":"0","summary":"Innoviva, Inc. recently received US FDA approval for NUZOLVENCE (zoliflodacin), a first-in-class, single-dose oral antibiotic to treat uncomplicated urogenital gonorrhea in adults and pediatric patients.\nThis marks one of the first new FDA-approved treatments for gonorrhea in nearly twenty years, underscoring Innoviva’s role in addressing antibiotic resistance and unmet infectious disease needs.\nWe’ll now explore how bringing a first-in-class, single-dose oral treatment for gonorrhea affects...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/how-investors-may-respond-to-innoviva-inva-winning-fda-appro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/how-investors-may-respond-to-innoviva-inva-winning-fda-appro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","INVA","ISBC","BK4211"],"gpt_icon":0},{"id":"2591981815","title":"Innoviva Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981815?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:10","pubTimestamp":1765887000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 07:10 ET (12:10 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INVA"],"gpt_icon":0},{"id":"2591359668","title":"Innoviva (INVA): Revisiting Valuation After a Strong Multi‑Year Share Price Run","url":"https://stock-news.laohu8.com/highlight/detail?id=2591359668","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591359668?lang=en_us&edition=fundamental","pubTime":"2025-12-14 16:17","pubTimestamp":1765700274,"startTime":"0","endTime":"0","summary":"Innoviva (INVA) has quietly put together a strong multiyear run, with the stock up around 61% over the past 3 years as its royalty driven respiratory portfolio continues to generate substantial cash.\nSee our latest analysis for Innoviva.\nOver the last year, Innoviva’s share price return has been robust, with an 18.56% year to date gain and a 3 year total shareholder return of 61.55%. This suggests momentum is still skewed to the upside despite the recent 1 month pullback.\nIf Innoviva’s steady...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/innoviva-inva-revisiting-valuation-after-a-strong-multiyear","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/innoviva-inva-revisiting-valuation-after-a-strong-multiyear","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["INVA","BK4007","DCF"],"gpt_icon":0},{"id":"2591684101","title":"Innoviva Gets FDA Approval for Gonorrhea Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591684101","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591684101?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:14","pubTimestamp":1765577640,"startTime":"0","endTime":"0","summary":"Innoviva received approval from the Food and Drug Administration for Nuzolvence, a treatment of gonorrhea.Nuzolvence has been approved as a single-dose oral medication to treat uncomplicated urogenital gonorrhea in patients 12 years and older, the biopharmaceutical company said Friday.Innoviva plans to commercialize the drug in the second half of 2026, either in collaboration with a commercialization partner or independently.The approval comes after Nuzolvence demonstrated non-inferiority compared with other treatments in a phase 3 trial of 930 patients.Gonorrhea is the second-most common sexually transmitted bacterial infection in the world, with more than 82 million new cases a year, according to the company. Without timely treatment, it can lead to serious and potentially permanent health complications.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2591684318","title":"U.S. FDA Approves Nuzolvence® (Zoliflodacin), a First-in-Class, Single-Dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents","url":"https://stock-news.laohu8.com/highlight/detail?id=2591684318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591684318?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:56","pubTimestamp":1765576560,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA58CTXM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INVA","BK4007"],"gpt_icon":0},{"id":"2591685496","title":"US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2591685496","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591685496?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:25","pubTimestamp":1765563935,"startTime":"0","endTime":"0","summary":"US FDA approves Innoviva's oral antibiotic for common sexually transmitted infectionsDec 12  - The U.S. Food and Drug Administration has approved Innoviva's INVA.O oral antibiotic for common sexually transmitted infection, offering patients a pill instead of the injection that is currently the only recommended treatment, the regulator said on Friday.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI1ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2591685498","title":"BRIEF-FDA Approved Nuzolvence (Zoliflodacin) To Treat Uncomplicated Urogenital Gonorrhea","url":"https://stock-news.laohu8.com/highlight/detail?id=2591685498","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591685498?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:25","pubTimestamp":1765563932,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Approved Nuzolvence  To Treat Uncomplicated Urogenital GonorrheaDec 12  - FDA:FDA: TODAY APPROVED NUZOLVENCE  GRANULES THAT DISSOLVE IN WATER TO TREAT UNCOMPLICATED UROGENITAL GONORRHEA - WEBSITEFurther company coverage: INVA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI1BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2591685179","title":"FDA: Today Approved Nuzolvence (Zoliflodacin) Granules That Dissolve in Water to Treat Uncomplicated Urogenital Gonorrhea - Website","url":"https://stock-news.laohu8.com/highlight/detail?id=2591685179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591685179?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:23","pubTimestamp":1765563820,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI1BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2590479375","title":"Innoviva Specialty Therapeutics Publishes Positive Phase 3 Zoliflodacin Data in The Lancet","url":"https://stock-news.laohu8.com/highlight/detail?id=2590479375","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590479375?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:35","pubTimestamp":1765496112,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innoviva Inc. published the original content used to generate this news brief via Business Wire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL2zbPCd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","LU0820561818.USD","BK4585","IE00BFTCPJ56.SGD","LU0949170772.SGD","LU2112291526.USD","LU0310800379.SGD","LU1934455863.HKD","LU1162221912.USD","LU1983299246.USD","LU1430594728.SGD","SG9999015978.USD","IE00BGHQF631.EUR","SG9999003800.SGD","IE0004445239.USD","LU1718418525.SGD","LU0689472784.USD","LU0738911758.USD","IE00B42XCP33.USD","BK4007","LU2089984988.USD","LU1585245621.USD","IE00BSNM7G36.USD","SG9999015952.SGD","LU1003077747.HKD","LU0058720904.USD","LU1267930573.SGD","LU1496350171.SGD","LU1244550494.USD","LU1244550577.SGD","LU0943347566.SGD","LU0795875086.SGD","INVA","LU0098860793.USD","LU0965509010.AUD","LU1732799900.SGD","BK4550","IE0002141913.USD","IE00B2B36J28.USD","IE00B3PB1722.GBP","BK4588","LU0545039389.USD","IE00BN8TJ469.HKD","LU1934455277.USD","BK4559","LU2237443465.HKD","IE00B19Z3B42.SGD","LU1291159041.SGD","IE00BJJMRZ35.SGD","ABBV"],"gpt_icon":0},{"id":"2590939547","title":"Innoviva Specialty Therapeutics Announces Publication in the Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea","url":"https://stock-news.laohu8.com/highlight/detail?id=2590939547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590939547?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:35","pubTimestamp":1765496100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA5SLHFX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INVA"],"gpt_icon":0},{"id":"2584346469","title":"Armata Pharmaceuticals Reports Positive Phase 2a Results for AP-SA02 in Staph Aureus Bacteremia","url":"https://stock-news.laohu8.com/highlight/detail?id=2584346469","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584346469?lang=en_us&edition=fundamental","pubTime":"2025-11-18 20:00","pubTimestamp":1763467259,"startTime":"0","endTime":"0","summary":"Armata Pharmaceuticals Inc., a clinical-stage biotechnology company specializing in bacteriophage therapeutics, announced that it will be featured in a key opinion leader webinar on November 25, 2025, focusing on Staphylococcus aureus  bacteremia and its investigational phage therapy, AP-SA02. The company previously presented positive results from its diSArm study at IDWeek 2025. The diSArm study was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, and efficacy of intravenous AP-SA02 in combination with best available antibiotic therapy  versus BAT alone in adults with complicated S. aureus bacteremia. Results indicated that the combination of AP-SA02 and BAT achieved higher and earlier cure rates compared to BAT alone, with AP-SA02 showing a 100% response rate without relapse at key follow-up points, while the placebo group exhibited an approximate 25% relapse or lack of response. AP-SA02 was reported to be well-tolera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6CDWYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARMP","BK4007","BK4139","INVA"],"gpt_icon":0},{"id":"2584492686","title":"A Look at Innoviva's (INVA) Valuation Following Strong Earnings and New Share Buyback Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2584492686","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584492686?lang=en_us&edition=fundamental","pubTime":"2025-11-17 15:19","pubTimestamp":1763363940,"startTime":"0","endTime":"0","summary":"Innoviva (INVA) grabbed attention after reporting a jump in both revenue and net income for the third quarter. The company also announced a $125 million share repurchase program that could impact shareholder value moving forward.\nSee our latest analysis for Innoviva.\nShares of Innoviva have shown renewed momentum lately, with a 28.8% 1-month share price return and the stock now trading at $22.25. This surge follows not only the strong earnings and fresh buyback announcement but also builds on...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/a-look-at-innovivas-inva-valuation-following-strong-earnings-1","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/a-look-at-innovivas-inva-valuation-following-strong-earnings-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["INVA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}